Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis

BACKGROUND: BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment of moderate or severe opioid use disorder. The primary objective of this phase III study was to assess the lon...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Psychopharmacol
Main Authors: Andorn, Anne C., Haight, Barbara R., Shinde, Sunita, Fudala, Paul J., Zhao, Yue, Heidbreder, Christian, Learned, Susan M., Fox, Norma Lynn, Nadipelli, Vijay R., Hassman, David, Rutrick, Daniel
Format: Artigo
Sprog:Inglês
Udgivet: Lippincott Williams & Wilkins 2020
Fag:
Original Contributions
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188268/
https://ncbi.nlm.nih.gov/pubmed/32282418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0000000000001195
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker